Investment Thesis Summary
On October 1, 2018, shares of Omeros Corporation (NASDAQ:OMER) dropped about 40% when the company announced positive phase 2 data for lead pipeline candidate narsoplimab . Investors were scared off by the fact that, following the initial 12-week course of treatment, there was no separation from placebo in terms of proteinuria reduction. However, the intent of the trial was not to show efficacy at week 12. Follow-up data showing proteinuria reduction at weeks 31-54 post-baseline demonstrate a clear separation from placebo. But the stock has yet to recover to its